STOCK TITAN

Viking Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences

Viking Therapeutics (NASDAQ: VKTX) has announced its participation in four major investor conferences in November 2024. The company will attend the Truist Healthcare Conference in New York (Nov 7) for a fireside chat, the UBS Global Healthcare Conference in Rancho Palos Verdes (Nov 11-14), the Stifel Healthcare Conference in New York (Nov 18-19) with a corporate presentation, and the Jefferies London Healthcare Conference (Nov 19-21).

Management will participate in one-on-one meetings at all events. A live webcast of the Stifel presentation will be available through Viking's website, with a replay accessible afterward in the Investors & Media section.

Viking Therapeutics (NASDAQ: VKTX) ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel mese di novembre 2024. L'azienda parteciperà al Truist Healthcare Conference a New York (7 novembre) per un incontro informale, al UBS Global Healthcare Conference a Rancho Palos Verdes (11-14 novembre), al Stifel Healthcare Conference a New York (18-19 novembre) con una presentazione aziendale, e al Jefferies London Healthcare Conference (19-21 novembre).

Il management parteciperà a incontri one-on-one in tutti gli eventi. Una diretta streaming della presentazione di Stifel sarà disponibile sul sito web di Viking, con una registrazione accessibile successivamente nella sezione Investitori & Media.

Viking Therapeutics (NASDAQ: VKTX) ha anunciado su participación en cuatro importantes conferencias de inversores en noviembre de 2024. La empresa asistirá a la Truist Healthcare Conference en Nueva York (7 de noviembre) para una charla informal, a la UBS Global Healthcare Conference en Rancho Palos Verdes (11-14 de noviembre), a la Stifel Healthcare Conference en Nueva York (18-19 de noviembre) con una presentación corporativa, y a la Jefferies London Healthcare Conference (19-21 de noviembre).

La dirección participará en reuniones uno a uno en todos los eventos. Una transmisión en vivo de la presentación de Stifel estará disponible a través del sitio web de Viking, con una repetición accesible posteriormente en la sección de Inversores y Medios.

Viking Therapeutics (NASDAQ: VKTX)가 2024년 11월에 열리는 네 개의 주요 투자자 컨퍼런스에 참석한다고 발표했습니다. 회사는 Truist Healthcare Conference에 뉴욕에서 (11월 7일) 비공식 대화를 위해 참석하고, UBS Global Healthcare Conference에 Rancho Palos Verdes에서 (11월 11-14일), Stifel Healthcare Conference에 뉴욕에서 (11월 18-19일) 기업 프레젠테이션을 가지고, Jefferies London Healthcare Conference에 (11월 19-21일) 참석합니다.

경영진은 모든 행사에서 개별 회의에 참여할 예정입니다. Stifel 프레젠테이션의 라이브 웹캐스트는 Viking의 웹사이트를 통해 제공되며, 이후 투자자 및 미디어 섹션에서 재생할 수 있습니다.

Viking Therapeutics (NASDAQ: VKTX) a annoncé sa participation à quatre grandes conférences pour investisseurs en novembre 2024. L'entreprise sera présente à la Truist Healthcare Conference à New York (7 novembre) pour une discussion informelle, à la UBS Global Healthcare Conference à Rancho Palos Verdes (11-14 novembre), à la Stifel Healthcare Conference à New York (18-19 novembre) avec une présentation d'entreprise, et à la Jefferies London Healthcare Conference (19-21 novembre).

La direction participera à des réunions individuelles lors de tous les événements. Un webinaire en direct de la présentation de Stifel sera disponible sur le site Web de Viking, avec un replay accessible par la suite dans la section Investisseurs & Médias.

Viking Therapeutics (NASDAQ: VKTX) hat seine Teilnahme an vier wichtigen Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird an der Truist Healthcare Conference in New York (7. November) für ein Fireside Chat teilnehmen, an der UBS Global Healthcare Conference in Rancho Palos Verdes (11.-14. November), an der Stifel Healthcare Conference in New York (18.-19. November) mit einer Unternehmenspräsentation, und an der Jefferies London Healthcare Conference (19.-21. November).

Das Management wird an allen Veranstaltungen an persönlichen Treffen teilnehmen. Ein Live-Webcast der Stifel-Präsentation wird über die Website von Viking verfügbar sein, mit einer späteren Wiederholung im Bereich Investoren & Medien.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. 

Details of the company's participation are as follows:

  • Truist Healthcare Conference
    Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
    Conference Date: November 7, 2024
    Fireside Chat Timing: 12:30 – 1:00 p.m. Eastern on Thursday, November 7, 2024
    Location: New York, NY

  • UBS Global Healthcare Conference
    Details: Viking management will participate in 1-on-1 meetings
    Conference Dates: November 11-14, 2024
    Location: Rancho Palos Verdes, CA

  • Stifel 2024 Healthcare Conference
    Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
    Conference Dates: November 18-19, 2024
    Presentation Timing: 8:35 – 9:05 a.m. Eastern on Tuesday, November 19, 2024, webcast available
    Location: New York, NY

  • Jefferies London Healthcare Conference 2024
    Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
    Conference Dates: November 19-21, 2024
    Presentation Timing: 9:00 – 9:25 a.m. GMT on Thursday, November 21, 2024
    Location: London, UK

A live webcast of the Stifel presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference. 

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.  In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302292012.html

SOURCE Viking Therapeutics, Inc.

FAQ

What investor conferences will Viking Therapeutics (VKTX) attend in November 2024?

Viking Therapeutics will attend four conferences: Truist Healthcare Conference (Nov 7), UBS Global Healthcare Conference (Nov 11-14), Stifel Healthcare Conference (Nov 18-19), and Jefferies London Healthcare Conference (Nov 19-21).

Will Viking Therapeutics (VKTX) provide a webcast of their conference presentations?

Yes, Viking will provide a live webcast of their Stifel Healthcare Conference presentation on November 19, 2024, accessible through their website with replay available afterward.

When is Viking Therapeutics' (VKTX) presentation at the Stifel 2024 Healthcare Conference?

Viking Therapeutics will present at the Stifel Healthcare Conference on Tuesday, November 19, 2024, from 8:35 to 9:05 a.m. Eastern time.

Where will the Truist Healthcare Conference featuring Viking Therapeutics (VKTX) take place?

The Truist Healthcare Conference featuring Viking Therapeutics will take place in New York, NY on November 7, 2024.

Viking Therapeutics, Inc

NASDAQ:VKTX

VKTX Rankings

VKTX Latest News

VKTX Stock Data

8.00B
111.44M
6%
74.9%
12.92%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO